DOT1L cooperates with the c-Myc–p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
DOT1L has emerged as an anticancer target for MLL-associated leukaemias; however, its functional role in solid tumours is largely unknown. Here we identify that DOT1L cooperates with c-Myc and p300 acetyltransferase to epigenetically activate epithelial–mesenchymal transition (EMT) regulators in breast cancer progression. DOT1L recognizes SNAIL, ZEB1 and ZEB2 promoters via interacting with the c-Myc-p300 complex and facilitates lysine-79 methylation and acetylation towards histone H3, leading to the dissociation of HDAC1 and DNMT1 in the regions. The upregulation of these EMT regulators by the DOT1L-c-Myc-p300 complex enhances EMT-induced breast cancer stem cell (CSC)-like properties. Furthermore, in vivo orthotopic xenograft models show that DOT1L is required for malignant transformation of breast epithelial cells and breast tumour initiation and metastasis. Clinically, DOT1L expression is associated with poorer survival and aggressiveness of breast cancers. Collectively, we suggest that cooperative effect of DOT1L and c-Myc-p300 is critical for acquisition of aggressive phenotype of breast cancer by promoting EMT/CSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“DOT1L drives the expression of genes associated with epithelial-mesenchymal transition (EMT) in breast cancer [79] and is also a key regulator of hematopoiesis [80], making it a therapeutic target in MLL-rearranged leukemias [81].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,699
Cancer stem cells: mirage or reality?
Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009) · Nature Medicine · doi:10.1038/nm0909-1010 · Cited by 979
Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State
Guo, W., Keckesova, Z., Donaher, J. L., Shibue, T., Tischler, V., Reinhardt, F., Itzkovitz, S., Noske, A., Zürrer-Härdi, U., Bell, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.008 · Cited by 957
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links
Scheel, C., & Weinberg, R. A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.04.001 · Cited by 881
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
hDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Cited by
Items 101–200 of 223
Characterizing crosstalk in epigenetic signaling to understand disease physiology
Lempiäinen, J. K., & Garcia, B. A. (2023) · Biochemical Journal · doi:10.1042/bcj20220550 · Cited by 30
Hsp90 as a “Chaperone” of the Epigenome
Isaacs, J. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.09.003 · Cited by 32
Gibbons, G. S., Chakraborty, A., Grigsby, S. M., Umeano, A. C., Liao, C., Moukha‐Chafiq, O., Pathak, V., Mathew, B., Lee, Y., Dou, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112023 · Cited by 28
Regulated cell death in glioma: promising targets for natural small-molecule compounds
Han, M., Li, S., Fan, H., An, J., Peng, C., & Peng, F. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1273841 · Cited by 30
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
Gruber, M., Ferrone, L., Puhr, M., Santer, F. R., Furlan, T., Eder, I. E., Sampson, N., Schäfer, G., Handle, F., & Čulig, Z. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0488 · Cited by 29
“However, the histone methyltransferase DOT1L in complex with p300 and c-Myc enhanced cellular stemness (Cho et al. 2015).”
Neeli, P. K., Sahoo, S., Karnewar, S., Singuru, G., Pulipaka, S., Annamaneni, S., & Kotamraju, S. (2022) · FEBS Journal · doi:10.1111/febs.16605 · Cited by 28
Wang, X., Wang, H., Xu, B., Jiang, D., Huang, S. H., Yu, H., Wu, Z., & Wu, Q. (2019) · Europe PMC (PubMed Central) · Cited by 26
DOT1L: a new therapeutic target for aggressive breast cancer
Lee, J., & Kong, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5860 · Cited by 26
Self-citationEmerging Moonlighting Functions of the Branched-Chain Aminotransferase Proteins
Conway, M. E. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8118 · Cited by 26
“An epigenetic role for DOT1L in breast cancer progression has also been proposed (21).”
Epigenetic Alterations of Cxcl5 in Cr(Vi)-Induced CarcinogenesisPreprint
Ge, X. Q., He, J., Wang, L., Жао, Л., Wang, Y., Wu, G., Liu, W., Shu, Y., Gong, W., Ma, X., et al. (2022) · SSRN Electronic Journal · doi:10.1016/j.scitotenv.2022.155713 · Cited by 25
Zhang, J., Yang, T., Han, M., Wang, X., Yang, W., Guo, N., Ren, Y., Cui, W., Li, S., Zhao, Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc9273 · Cited by 27
Li, M., Guo, Y. F., Feng, Y., & Zhang, N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00180 · Cited by 25
Bromodomain (BrD) Family Members as Regulators of Cancer Stemness—A Comprehensive Review
Czerwińska, P., & Mackiewicz, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020995 · Cited by 23
Zhou, R., Xie, F., Liu, K., Zhou, X., Chen, X., Chen, J., Xi, S., Huang, Z., & Rong, X. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01290-y · Cited by 22
“Currently, several histone modification regulators, including DOT1L [34], DNMT1 [36], EZH2 [33], and KDM5B [35], have been reported to play a role in the TGFβ-stimulated ZEB2 transcriptional upregulation of many cancers.”
BackgroundWang, C., Kao, H., Chen, T.-W., Huang, Y., Cheng, H.-W., Yi, J., Hung, S., Wu, C., Lee, Y.-S., & Chang, K. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0063 · Cited by 22
Wille, C. K., & Sridharan, R. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.12.004 · Cited by 22
“, 2019) and breast cancer cell lines (Cho et al., 2015), by DOT1Li.”
BackgroundEpigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications
Sarkar, S., Venkatesh, D., Kandasamy, T., & Ghosh, S. S. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2908287 · Cited by 22
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
Sirtuins and Hypoxia in EMT Control
Aventaggiato, M., Barreca, F., Sansone, L., Pellegrini, L., Russo, M. A., Cordani, M., & Tafani, M. (2022) · Pharmaceuticals · doi:10.3390/ph15060737 · Cited by 20
“Several studies have shown that EMT regulators are closely linked to the induction of stem-cell properties in many human cancers [98,99].”
BackgroundSzulik, M. W., Davis, K., Bakhtina, A. A., Azarcon, P., Bia, R. D., Horiuchi, E., & Franklin, S. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00382.2020 · Cited by 20
Zhang, G., & Huang, R. (2016) · RSC Advances · doi:10.1039/c5ra20625a · Cited by 20
Yao, X., Pham, T. M., Temple, B., Gray, S., Cannon, C., Hardy, C., Fletcher, K., Ireland, S. K., Hossain, A., Chen, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19703 · Cited by 20
“com/oncotarget visualized with ethidium bromide [34].”
Byun, W. S., Kim, W. K., Yoon, J.-S., Jarhad, D. B., Jeong, L. S., & Lee, S. K. (2020) · Biomolecules · doi:10.3390/biom10040530 · Cited by 20
“EMT is a complex and reversible process that is triggered by signals, such as hypoxic condition, TGF- β, and TNF-α [19].”
BackgroundOgoh, H., Yamagata, K., Nakao, T., Sandell, L. J., Yamamoto, A., Yamashita, A., Tanga, N., Suzuki, M., Abe, T., Kitabayashi, I., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11745-5 · Cited by 19
Li, Z., Gu, Z., Wang, L., Guan, Y., Lyu, Y., Zhang, J., Wang, Y., Wang, X., Xiong, J., & Liu, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119365 · Cited by 19
“BCAT1 is one of the targets of DOT1L [13].”
BackgroundChen, S., Wang, D., Liu, Y., Zhao, R., Wu, T., Hu, X., Pan, Z., & Cui, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.603131 · Cited by 18
Amjadi‐Moheb, F., Paniri, A., & Akhavan‐Niaki, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3613 · Cited by 17
“As a complex, DOT1L and c-Myc-p300 promote the expression of EMT-related factors in breast cancer (178).”
BackgroundYang, Y., Wu, C.-Y., Wang, X., Deng, J., Cao, W.-J., Tang, Y.-Z., Wan, C.-C., Chen, Z.-T., Zhan, W.-Y., Shan, H., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.019 · Cited by 16
Polydatin: A natural compound with multifaceted anticancer properties
Imtiyaz, K., Shafi, M., Fakhri, K. U., Uroog, L., Zeya, B., Anwer, S. T., & Rizvi, M. M. A. (2024) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2024.06.006 · Cited by 16
Role of histone acetyltransferase inhibitors in cancer therapy
Shanmugam, M. K., Dharmarajan, A., Warrier, S. R., Bishayee, A., Kumar, A. P., Sethi, G., & Ahn, K. S. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.08.002 · Cited by 18
DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer
Kurani, H., & Slingerland, J. M. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-3304 · Cited by 16
“Importantly, others showed that DOT1L overexpression induced malignant transformation of the nontumorigenic breast epithelial MCF10A line, in vitro and in vivo (112).”
InfluentialHistone acetylation modulators in breast cancer
Yuan, X., & Rosen, J. M. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02006-9 · Cited by 16
“In addition, EP300 induces the expression of key EMT regulators in non-tumorigenic breast epithelial cells MCF10A by histone H3 acetylation and interacting with other transcription factors such as c-Myc [38].”
Byun, W. S., Lee, G. H., Park, H., & Lee, S. K. (2020) · Pharmaceuticals · doi:10.3390/ph14010018 · Cited by 15
“In particular, aberrantly expressed histone methyltransferases (HMTs) in TNBC have been reported to mediate cell development, proliferation, and metastasis and are thus considered novel therapeutic targets for TNBC [13,14].”
BackgroundIL20RB signaling enhances stemness and chemotherapy resistance in pancreatic cancer
Li, X., Huang, G., Xu, Z.-L., Zhao, C., Dong, X.-Y., Cui, B., & Lin, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04800-5 · Cited by 14
“Previous studies have found that the oncogene MYC drives stemness in breast and pancreatic cancer [20, 21].”
BackgroundPost-translational modifications of EMT transcriptional factors in cancer metastasis
Chang, R., Zhang, P., & You, J. (2016) · Open Life Sciences · doi:10.1515/biol-2016-0033 · Cited by 14
Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase
Trager, M. H., Sah, B., Chen, Z., & Liu, L. (2021) · Endocrinology · doi:10.1210/endocr/bqab088 · Cited by 14
Xu, B., Zhang, C., Ao, J., Zhang, X., Liang, F., Wang, X., Li, D., Liu, C., Liu, X., Xia, J., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102115 · Cited by 14
Loeser, H., Waldschmidt, D., Kuetting, F., Heydt, C., Zander, T., Plum, P. S., Alakus, H., Buettner, R., & Quaas, A. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1194 · Cited by 14
“In breast carcinoma, DOT1L is associated with an aggressive phenotype and has also been revealed to be a potential therapeutic target (4,20,21).”
Gu, X., Hua, Y., Yu, J., Yang, L., Ge, S., Jia, R., Chai, P., Zhuang, A., & Fan, X. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.11.008 · Cited by 13
“Through interaction with the c-Myc-p300 complex, DOT1L accelerates H3K79 methylation and epigenetically activates epithelialmesenchymal transition (EMT) mediators in breast cancer [32].”
BackgroundDOT1 L Regulates Ovarian Cancer Stem Cells by Activating β-catenin Signaling
Zhang, Y., Wang, Y., Valdivia, A., Huang, H., & Matei, D. E. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0418 · Cited by 13
Moon, S., Choi, H.-J., Kye, Y.-H., Jeong, G., Kim, H.-Y., Myung, J. K., & Kong, G. (2023) · Cancers · doi:10.3390/cancers15041168 · Cited by 13
“Immunoblotting was carried out as previously described [26].”
MethodSelf-citationWalser, T. C., Jing, Z., Tran, L. M., Lin, Y. Q., Yakobian, N., Wang, G., Krysan, K., Zhu, L. X., Sharma, S. P., Lee, M.-H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0315 · Cited by 13
Wang, Y., Luo, Y., Guan, W., & Zhao, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8940 · Cited by 13
“The Zeb1 antibody (1:1,000), E-cadherin (both from Cell Signaling Technology, Inc., Danvers, MA, USA), N-cadherin, vimentin (both from Abcam, Cambridge, UK) antibodies were incubated (dilution rates, 1:1,000).”
BackgroundInfluentialEsse, R., Gushchanskaia, E. S., Lord, A., & Grishok, A. (2019) · RNA · doi:10.1261/rna.070292.119 · Cited by 13
Chen, Y., Zhao, Y., Yao, M., Yf, W., Ma, M., Yu, C.-C., Jiang, H., Wu, W., Shen, J., Xu, X., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01479-w · Cited by 14
Decoding the Epigenome of Breast Cancer
Cortellesi, E., Savini, I., Veneziano, M., Gambacurta, A., Catani, M. V., & Gasperi, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062605 · Cited by 14
Han, H., Byun, W. S., Lee, G. H., Kim, W. K., Jang, K., Yang, S., Yang, J., Ha, M. W., Hong, S., Lee, J., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116072 · Cited by 12
Self-citationDeciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics
Kalita, B., & Coumar, M. S. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00611-2 · Cited by 13
Sarkar, S., Kandasamy, T., & Ghosh, S. S. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23848 · Cited by 11
Loss of DOT1L disrupts neuronal transcription and leads to a neurodevelopmental disorder
Maroni, M. J., Barton, M., Lynch, K., Deshwar, A. R., Campbell, P. D., Millard, J., Lee, R., Cohen, A., Ahmad, R., Paranjapye, A., et al. (2025) · Brain · doi:10.1093/brain/awaf212 · Cited by 8
Sun, L., Wang, H., Li, H., Yang, R., Dong, D., Dong, D., Fan, Y., Li, E., Wang, H., Wu, Y., et al. (2025) · Biology Direct · doi:10.1186/s13062-025-00683-2 · Cited by 8
“S15C-F), which plays important role on EMT-induced cancer stem cell like properties [41].”
Ding, X., Cai, X.-M., Wang, Q., Liu, N., Zhong, W., Xi, X., & Lu, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155833 · Cited by 11
Tao, M., Shi, Y., Chen, H., Li, J., Wang, Y., Ma, X., Du, L., Wang, Y., Yang, X., Hu, Y., et al. (2024) · Molecular Biomedicine · doi:10.1186/s43556-023-00161-z · Cited by 8
“It had been reported that DOT1L could maintain leukemic gene expression, promote the phenotype differentiation of neuronal, myocardial cells and breast cancer cells [26].”
Li, P., Zhang, Z., & Sun, P. (2024) · Journal of Cancer · doi:10.7150/jca.90170 · Cited by 7
“Prognostic and therapeutic consequences of DOT1L overexpression within ovary [47] as well as malignancies of the colon [48], breast [49, 50] and neuroblastoma [51] are known.”
BackgroundDOT1L as a Therapeutic Target: Insights into Epigenetic Regulation and Cancer Treatment
Choi, H., Nguyen, M. T., Kim, B., Kim, S. H., Kim, J., Lee, J., & Park, M. K. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.075 · Cited by 6
“After binding to H2BK120ub, DOT1L recruits various cofactors including AF9/10 (Mueller et al ., 2007), c-Myc (Cho et al ., 2015), and NPM1 (Izzo et al ., 2023) to gene promoters to facilitate transcriptional elongation.”
Self-citationDOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer
Hou, Y., Liu, J., Huang, S., Wang, L., Hu, J., & Liu, X. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231167249 · Cited by 6
“…the only methyltransferase catalyzing the mono-, di-, and trimethylation of histone 3 lysine 79 (H3K79) (H3K79me2 and -me3), was overexpression in many cancer types, including leukemia, 3 prostate cancer, 4 breast cancer, 5 and renal cell carcinoma 6 and was associated with poor clinical outcomes.”
BackgroundSrivastava, A., Ahmad, R., Yadav, K., Siddiqui, S., Trivedi, A., Misra, A., Mehrotra, S., Ahmad, B., & Khan, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112232 · Cited by 6
The Landscape of Histone Modification in Cancer Metastasis
Qiu, Z., Wang, J., & Wu, Y. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.78383 · Cited by 6
“p300 cooperates in an epigenetic manner with a DOT1L-c-Myc complex to induce EMT in breast metastasis [12].”
BackgroundSalgado, C., Kwesi‐Maliepaard, E. M., Jochemsen, A. G., Visser, M., Harland, M., van Leeuwen, F., van Doorn, R., & Gruis, N. A. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000640 · Cited by 6
MicroRNAs in hereditary diffuse gastric cancer
Suárez-Arriaga, M.-C., Ribas-Aparicio, R.-M., & Tachiquín, M. E. R. (2016) · Biomedical Reports · doi:10.3892/br.2016.706 · Cited by 6
“The regulation of the MAP3K6 , FBXO24 and DOT1L genes mediated by microRNA remains to be elucidated; however, cooperation of the protein DOT1L with c-Myc and an acetyltransferase has been described for activation of the EMT in the initiation and progression of breast cancer to metastasis (30).”
Li, J., Deng, P., Fan, T., Qu, Y., Tan, M., Liang, Y., Gao, P., Peng, Y., Qin, M., Jie, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202500941 · Cited by 5
Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer
Walsh, L., Gallagher, W. M., O’Connor, D. P., & Chonghaile, T. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1156534 · Cited by 6
Kıvrak, M., Nalkıran, İ., & Nalkıran, H. S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030173 · Cited by 5
“In another study, EPZ004777-mediated DOT1L inhibition was found to be effective in increasing E-cadherin levels in breast cancer cells by suppressing key transcription factors involved in the epithelial–mesenchymal transition (EMT) [25].”
Schwab, R. B., Koehler, M. T., Ali, S. M., & Murray, B. W. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.06.008 · Cited by 5
c-Myc: Central regulator of autophagy and senescence in cancer
Ji, S., Sun, T., Zhang, Q., Wu, M., Cao, Y., Gao, R., Wang, L., Nicot, C., & Sethi, G. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218315 · Cited by 4
Altriche, N., Gallant, S., Augustine, T. N., & Xulu, K. R. (2024) · Biomarker Insights · doi:10.1177/11772719241256798 · Cited by 5
Epithelial-Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs): The Traveling Metastasis
Mego, M., Reuben, J. M., & Mani, S. A. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-50956-3_4 · Cited by 4
Pandey, P., Alkhathami, A. G., Saeed, M., Alshaghdali, K., Kumar, S., Tallei, T. E., Bae, H., Park, M. N., Kumar, G., Kim, B., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s554844 · Cited by 3
“88 E-cadherin is a tumor suppressor that promotes cell-to-cell contact between adjacent cells.”
Self-citationTurna, S., & Demokan, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1788808 · Cited by 3
“In breast cancer, DOT1L interacts with the c-Myc – p300 complex to activate EMT-TFs (SNAIL, ZEB1, ZEB2) via coordinated H3K79 methylation and histone acetylation, thereby inducing EMT and cancer stem cell – like properties (98).”
Wang, Y., Chen, Y., & Zhao, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01048-3 · Cited by 3
Zhu, Z., Zhang, Q., & Sui, Z. (2024) · Marine Pollution Bulletin · doi:10.1016/j.marpolbul.2024.117080 · Cited by 3
Emerging patterns and implications of breast cancer epigenetics
Venkatesh, T., Thankachan, S., Kabekkodu, S. P., Chakraborti, S., & Suresh, P. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819753-0.00015-5 · Cited by 7
Histone methylation modifiers in medical therapeutics
Trojer, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00020-7 · Cited by 5
Han, J., Yang, S., Byun, W. S., Jang, S. C., Bae, E. S., Park, H., & Lee, S. K. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106991 · Cited by 2
Chromatin Regulatory Targets for Anticancer Therapeutics
Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 4
Liu, L., Yuan, P., Doğan, S., Zhu, F., & Duan, Q. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0099-9 · Cited by 2
“tribute to breast cancer metastasis [63].”
BackgroundCommon and distinct functions of mouse Dot1l in the regulation of endothelial transcriptome
Yoo, H., La, H., Park, C., Yoo, S., Lee, H., Song, H., Tae, J., Choi, Y., & Hong, K. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1176115 · Cited by 2
“, 2011), breast cancer (Cho et al., 2015; Nassa et al., 2019), ovarian cancer (Zhang et al.”
BackgroundFarris, J. C. (2016) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.5579 · Cited by 2
Yoshido, A., Ishiguro, K., Kitajima, H., Niinuma, T., Kumegawa, K., MAEZAWA, M., Tsukahara, T., Toyota, M., Yorozu, A., Sasaki, H., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-02017-5 · Cited by 1
“Cho et al.. showed that in breast cancer cells, DOT1L cooperates with c-Myc and p300 acetyltransferase to activate a series of EMT-related genes, including SNAIL, ZEB1 and ZEB2, and that the DOT1L-c-Myc-p300 complex enhances the CSC properties [22].”
Lai, J., Tao, C., Jiang, F., & Li, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118446 · Cited by 1
Histone Methylation Modifiers in Medical Therapeutics
Trojer, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00037-5 · Cited by 1
Targeting Epigenetic Modifiers for Cancer Treatments
Chee, C. S., & Leung, D. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0130-9 · Cited by 1
Hosseini, M., Feghhi-Najafabadi, S., & Azad, M. (2024) · PubMed Central · doi:10.30498/ijb.2024.447513.3897 · Cited by 4
The role of DOT1L in MLL-AF4 leukaemia
Godfrey, L. (2018) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-9rk98bvjm · Cited by 3
Sepulveda, G. P., Gushchanskaia, E. S., Mora-Martin, A., Esse, R., Nikorich, I., Ceballos, A., Kwan, J., Blum, B. C., Dholiya, P., Emili, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.06.579191 · Cited by 1
Zhu, L., Muhammad, H., Perry, T. A., Ardasheva, A., Symons, R. A., McClure, J. J., Kania, K., Clark, S. M., Colella, F., Koneva, L. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.21.671507 · Cited by 2
The histone methyltransferase DOT1L is required for DNA damage recognition and repair
Raul, S. K. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6102
p300 and CBP targeting in castration therapy resistant prostate cancer
Furlan, T., Kirchmair, A., Sampson, N., Puhr, M., Gruber, M., Trajanoski, Z., Santer, F. R., & Čulig, Z. (2019) · European Urology Supplements · doi:10.1016/s1569-9056(19)33327-5
Planificación financiera y de marketing para alcanzar la rentabilidad
Fox, H. W. (1976) · Alta dirección
Du, H., & Zhang, L. (2022) · Journal of Hard Tissue Biology · doi:10.2485/jhtb.31.101
Pifer, P. M. (2016) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6420
Jeong, G., Park, M. K., Choi, H.-J., An, H. W., Park, Y., Choi, H.-J., Park, J., Kim, H.-Y., Son, T., Lee, H., et al. (2023) · doi:10.1158/0008-5472.c.6512607.v1
Self-citationAmjadi‐Moheb, F., Paniri, A., & Akhavan‐Niaki, H. (2023) · doi:10.1158/0008-5472.c.6512979.v1
Anaz, A. A., Suryaprakash, R. T. C., Shearston, K., & Kujan, O. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080384123010008
Epigenetics in the Diagnosis, Prognosis, and Therapy of Cancer
Fu, L., & Liu, B. (2023) · Epigenetics and human health · doi:10.1007/978-3-031-42365-9_4
Zhou, R., Xie, F., Liu, K., Zhou, X., Chen, X., Chen, J., Xi, S., Huang, Z., & Rong, X. (2022) · Figshare · doi:10.6084/m9.figshare.19845907
Identification of multi-cancer risk genes
Rivera, S. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.248736
BCAT1 is a novel target of MLL fusions and essential for leukemic stem cell transformation
Schmid, T. (2022) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00031737
Zhou, R., Xie, F., Liu, K., Zhou, X., Chen, X., Chen, J., Xi, S., Huang, Z., & Rong, X. (2022) · Figshare · doi:10.6084/m9.figshare.19845922
Metadata
- Authors
- Cho, M.-H., Park, J.-H., Choi, H.-J., Park, M.-K., Won, H.-Y., Park, Y.-J., Lee, C. H., Oh, S.-H., Song, Y.-S., Kim, H. S., Oh, Y.-H., Lee, J.-Y., & Kong, G.
- Affiliations
- Hanyang University (KR)
- Dongguk University (KR)
- Gachon University (KR)
- Corresponding author
- Lee, Jeong-Yeon
- Kong, Gu
- ORCID
- Venue
- Nature Communications
- Published
- 2015-07-22
- Volume
- 6
- Issue
- 1
- Pages
- 7821-7821
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4525167
- OpenAlex
- W1620051969
- Cited by
- 211
- References
- 39
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 19 · 2023: 21 · 2022: 29 · 2021: 24 · 2020: 22 · 2019: 20 · 2018: 10 · 2017: 18 · 2016: 23 · 2015: 3
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Royal Society of Chemistry’s Journals, Books and Databases (The Royal Society of Chemistry) (submittedVersion)
- The Royal Society of Chemistry’s Journals, Books and Databases (The Royal Society of Chemistry) (submittedVersion, cc-by)
- Funders
- National Research Foundation
- National Research Foundation of Korea
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- DOT1L, c-Myc, P300, epithelial-mesenchymal transition, breast cancer progression, histone H3 lysine 79 methylation, histone acetylation, snails, ZEB1, ZEB2, HDAC1, DNMT1, breast cancer stem cells, metastasis, tumor initiation
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Methyltransferases, Neoplasm Metastasis, Histone-Lysine N-Methyltransferase, Neoplastic Stem Cells, Case-Control Studies, Proto-Oncogene Proteins c-myc, Mice, SCID, Mice, Inbred NOD, Disease Progression, Epigenesis, Genetic, Cell Line, Tumor, E1A-Associated p300 Protein, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.